American Society of Hirudotherapy

WP Peptide LR

Whitmania pigra-derived anticoagulant peptide showing neuroprotection in rat MCAO ischemia-reperfusion model (Liu 2026) — thrombin modulation + fibrinolysis homeostasis.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • WP Peptide LR0.6 kDa
Molecular weight (kilodaltons) of WP Peptide LR (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Synthetic analog
Safety domains
Bleeding

Clinical translation limit

LR peptide's neuroprotection in rat MCAO does NOT establish clinical efficacy in human ischemic stroke. No FDA-approved derivative exists; numerous animal-model stroke neuroprotectants have failed in human RCTs.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
600 Da
Source species
Whitmania pigra
Discovered
2026 · Liu R et al.

Biological Targets

  • → thrombin / coagulation-fibrinolysis homeostasis (rat MCAO model)

Key Citations

  1. Liu R et al. (2026), Brain Res · PMID 41765218

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.